Izifundo zikhombisa ukungafani okutholakala kwe-osteoarthritis kanye nesifo samathambo.
Ingabe ukudla kwakho kuwanele izithelo nemifino enesithambile C? Ingabe kufanele uthathe isithako se-vitamin C ? Ingabe kukhona ubuhlobo obuseduze noma obuvikelayo phakathi kwe-vitamin C ne-arthritis? Lokho kubalulekile izinto okufanele uzicabangele.
I-Vitamin C ne-Arthritis
Ucwaningo oluthile luveza ukuthi i-vitamin C ivikela ukulwa nesifo samathambo futhi ivimbela izimpawu ngenkathi enye isifundo ithi i-vitamin C ingase ibe yingozi kakhulu kwe-arthritis.
Kungani ukungafani? Kukhona ngempela isizathu. Lezi zifundo zagxila ezinhlotsheni ezimbili ezihlukene ze-arthritis , i- rheumatoid arthritis (RA) ne- osteoarthritis (OA), okuyizinqubo ezahlukene zezifo.
I-Vitamin C ne-Osteoarthritis
I-osteoarthritis ibonakala ukuwohloka kancane kancane kwamalungu, isizathu sokuthi ibuye ibizwa ngokuthi uhlobo lokugqoka i-arthritis. Imiphumela yokufunda, evezwa ngo-June 2004 ye- Arthritis & Rheumatism , ibonise ukuthi ukusebenzisa isikhathi eside kwevithamini C kungalimaza ubukhulu be- osteoarthritis emadolweni .
Abacwaningi bahlaziya umphumela wezinyanga eziyisishiyagalombili ezinamavithamini C aphansi, aphakathi nendawo aphakeme aphezulu ezingulube. Izingulube zaseGuinea, njengabantu, azikwazi ukuzakhela vithamini C ngokwayo.
Iqembu lezinga eliphezulu lihlakulele i- osteoarthritis enamandla kakhulu emadolweni kanye nomonakalo omkhulu kakhulu we-cartilage. Abacwaningi kulolu cwaningo baphetha ngokuthi ukudla okudliwayo kwe-vitamin C akufanele kubekwe ngaphezu kwesabelo samanje sokudla esinconywayo:
- 90 mg ngosuku ngamadoda.
- 75 mg. ngosuku ngabesifazane.
I-Vitamin C ne-Rheumatoid Arthritis
I-arthritis ye-rheumatoid isifo esizimele esisodwa esiholela ekuvuvukeni kwezingxenye zamalungu, okuholela ekubhujisweni nasekufeni kwezingxenyana ezithintekayo. Kuye kwabikwa ku- Annal of the Rheumatic Diseases , ukuthi ukusetshenziswa kokudla okuphezulu ku-vitamin C kubonakala kukuvikela ekuvukeleni kwe-polyarthritis , uhlobo lwe-arthritis ye-rheumatoid ehlanganisa amalunga amabili noma ngaphezulu.
Lolu cwaningo lwabandakanya abahlanganyeli abangaphezu kuka-23,000 ababengenele ucwaningo olukhulu lomdlavuza e-UK Abahlanganyeli babegcina idayari yokudla futhi babengenaso isifo samathambo ngesikhathi sokuqala kokufunda.
Abacwaningi baqhathanisa izidlo zabathintekayo abangu-73 abaqala ukuvuvukala i-polyarthritis ngesikhathi seminyaka eyisishiyagalolunye kanti abangu-146 abahlala benesifo samagciwane. Ngemuva kokuhlaziywa, abacwaningi baphetha ngokuthi abantu abanesifo samathambo badla izithelo nemifino encane kunalabo abangazange bahlakulele lesi sifo. Abahlanganyeli abadla izithelo kanye nemifino encane babe nomngcipheko wokuba nesifo samathambo esivuthayo kabili.
Kwakukhona umehluko omkhulu ekutheni abantu abangakanani abasebenzisa i-arthritis badliwa yiziqhathaniswa nalabo abangazange bahlakulele isifo samathambo. Abahlanganyeli abadla amavithamini C aphansi kunazo zonke babengamathuba amathathu okuthuthukisa isimo se-arthritic kunalabo abadla inani eliphakeme lamavithamini C. Umphumela omuhle we-vitamin C kwi-arthritis ye-rheumatoid kungenzeka ukuthi:
- I-Vitamin C iyinhlangano enamandla yokulwa ne-antioxidant , elwa nokulwa nokuvuvukala kwesifo se-rheumatoid.
- I-Vitamin C isebenza indima njenge-cofactor ekwenzeni i-collagen, iphrotheni eyinhloko emathisini ahlangene kanye nethambo.
- I-Vitamin C inendima ekulwa nokutheleleka futhi ingasebenza ukulawula ukuvuvukala okuhlobene nokutheleleka.
- Abanye bakholelwa ukuthi ukutheleleka kungabangela ama-flath of arthritis e-rheumatoid.
Isiphetho
Ukulinganisela kokungenwa kwe-vitamin C kunconywa ukuthi kugcinwe amathambo namajoyina enempilo. Ukudla ngokweqile kwe-vitamin C kungaba yinkinga. Ukudla izithelo nemifino ukuze uthole ama-vitamin C okunconywa nsuku zonke ukukhuthazwa ngokwemvelo.
Imithombo:
I-Vitamin C i-Worsens Knee-osteoarthritis e-Animal Study, iDuke University Medical Centre. 6/3/2004.
I-Vitamin C kanye nobungozi bokuqala ukuvuvukala i-polyarthritis: ukutadisha okwenziwe ngezitshalo, ukuhlaziywa kwezifo, ama-Annals of the Rheumatic Diseases, ngo-2004; 63: 843-847. http://ard.bmj.com/content/63/7/843